By Sheila Dang (Reuters) – For years, investors have wondered about the long-term prospects for Snap Inc and Pinterest Inc, smaller digital ad players which have had to pick up the ad dollar scraps left over from giant tech rivals. This week, David triumphed over Goliath as Snap and Pinterest reported financial results that demonstrated …
Analysis-Digital ad minnows Snap, Pinterest soar past giant Meta Read More »
By John McCrank NEW YORK (Reuters) – Exchange operator Cboe Global Markets said on Friday its fourth-quarter profit surged 90%, topping Wall Street estimates on higher transaction volumes, notably in options, and lower-than-expected expenses. Cboe, which provides trading platforms and products in equities, derivatives and foreign exchange across North America, Europe and Asia Pacific, said …
Exchange operator Cboe’s quarterly revenue tops views on higher volumes Read More »
By Elizabeth Culliford (Reuters) – Facebook’s parent Meta Platforms said on Friday it is launching a tool for people using its virtual reality social platforms to maintain personal space boundaries, as concerns have mounted about user safety and sexual harassment in the metaverse. Its new “personal boundary” tool will make users feel like they have …
Facebook owner Meta adds tool to guard against harassment in metaverse Read More »
By Praveen Paramasivam (Reuters) -Cruise operator Royal Caribbean Group said on Friday the lightning spread of the Omicron coronavirus variant would delay its return to profitability by a few months, another blow for one of the companies worst affected by the pandemic. The bleak prediction, as well as a larger-than-expected quarterly loss, sent Royal Caribbean’s …
Royal Caribbean’s return to profit delayed by Omicron surge Read More »
By Tom Polansek CHICAGO (Reuters) – Tyson Foods Inc is expected to post strong results for its beef business in a quarterly earnings report on Monday, as the Biden administration’s criticism of high meat prices and fat profits for processors continues to mount. Increased operating margins could attract more unwanted scrutiny from Washington for Tyson …
Tyson Foods’ beef profits expected to amplify concerns about high meat prices Read More »
By Siddharth Cavale and Uday Sampath Kumar (Reuters) – From Hershey to Clorox and Kleenex maker Kimberly-Clark, major consumer-products companies have announced plans to boost U.S. prices further or more broadly than previously proposed this year, signaling that the fastest inflation rate in a generation may not ebb soon. Product makers generally hold conversations with …
From Kisses to Kleenex, consumer-product makers plot additional U.S. price hikes Read More »
(Reuters) -Hertz Global Holdings on Friday named former Goldman Sachs finance chief Stephen Scherr as its top boss, replacing interim CEO Mark Fields, sending shares of the car rental firm up 4% before the bell. Scherr will assume his new role as CEO and a board member on Feb. 28, Hertz said in a statement, …
Hertz wheels in ex-Goldman Sachs CFO as top boss, shares jump Read More »
(Reuters) -Regeneron Pharmaceuticals Inc on Friday reported fourth-quarter revenue that beat analysts’ estimates, boosted by demand for blockbuster drugs Dupixent and Eylea, coupled with higher sales of its COVID-19 therapy. Sales of Dupixent, which is used to treat eczema, jumped 51% to $1.77 billion, while that of eye drops Eylea increased 13% to $2.45 billion. …
Regeneron revenue beats estimates on strong sales of Eylea, COVID therapy Read More »
By Balazs Koranyi and William Schomberg FRANKFURT/LONDON (Reuters) – In just a few short weeks, the balance of power at the world’s top central banks has shifted to conservatives, heralding the biggest wave of policy tightening in years. Yet the rapid retreat of doves in the face of sky-high inflation increases the risk of a …
Analysis-Central bank balance of power shift raises policy error risk Read More »
(Reuters) – Drugmaker Bristol Myers Squibb Co on Friday posted slightly better than expected fourth-quarter earnings on strong sales of blood thinner Eliquis and cancer drug Opdivo. The company said it earned $4.07 billion in the quarter, or $1.83 a share, up from $3.33 billion or $1.46 a share, a year earlier. Analysts on average …
Bristol Myers posts slightly better-than-expected 4th-qtr results Read More »
